Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Inositol | 100g Pack Size. Group: Biochemicals, Carbohydrates, Sugars. Formula: C6H12O6. CAS No. 87-89-8. Prepack ID : 11267767-100g. Molecular Weight : 180.16. |  |
| Inositol | 500g Pack Size. Group: Biochemicals, Carbohydrates, Sugars. Formula: C6H12O6. CAS No. 87-89-8. Prepack ID : 11267767-500g. Molecular Weight : 180.16. | |
| Inositol | Inositol, CAS 87-89-8, Vitamins. Formerly Lansdowne Chemicals | OQEMA England, Oxfordshire |
| Inositol Impurities | Inositol Impurities, pivotal in the realm of therapeutic research, significantly influence the development of interventions for mood disorders and metabolic diseases. These impurities facilitate the comprehension of drug stability and efficacy, especially in psychiatric and diabetic medications, thereby bolstering the essential framework for pharmacological advancements. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| D-(+)-chiro-Inositol | 1g Pack Size. Group: Biochemicals, Building Blocks, Carbohydrates. Formula: C6H12O6. CAS No. 643-12-9. Prepack ID : 26002642-1g. Molecular Weight : 180.16. | |
| L-alpha-Phosphatidyl inositol | 1g Pack Size. Group: Biochemicals. CAS No. 97281-52-2. Prepack ID : 86215300-1g. | |
| Myo-Inositol | Myo-Inositol. Uses: Pharmaceuticals, Personal Care, Industrial. Grades: Pharma, Cosmetic, Food, Feed, Technical. CAS No. 87-89-8. Pack Sizes: Bulk. Cenik is your partner of choice for Hard-to-find chemicals. We don't just provide products, we supply solutions to your technical and regulatory specifications. |  Cenik Chemicals |
| 4-Aminophenyl a-D-mannopyranoside 6-phosphate | 4-Aminophenyl a-D-mannopyranoside 6-phosphate is a chemical compound used in the synthesis of phosphoinositide. This product is also used in the study of phosphatidylinositol (PI) signaling pathways, and has been shown to inhibit phospholipase C activity. Additionally, it has been found to be involved in the regulation of insulin secretion. Group: Pharmaceutical. CAS No. 74160-60-4. Pack Sizes: 100 mg. Product ID: B1370-000873. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AC-55541 | AC-55541 is a novel small-molecule protease-activated receptor 2(PAR2) agonist which displays no activity at other PAR subtypes or at over 30 other receptors involved in nociception and inflammation. It activated PAR2 signaling in cellular proliferation assays, phosphatidylinositol hydrolysis assays, and Ca(2+) mobilization assays, with potencies ranging from 200 to 1000 nM. It was well absorbed when administered intraperitoneally to rats, reaching micromolar peak plasma concentrations. It was stable to metabolism by liver microsomes and maintained sustained exposure in rats. Uses: Ac-55541 stimulates cell proliferation, phosphatidylinositol hydrolysis, and calcium mobilization. Group: Pharmaceutical. CAS No. 916170-19-9. Pack Sizes: 300 mg. Product ID: B0084-271988. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alpelisib | Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BYL719 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Group: Pharmaceutical. CAS No. 1217486-61-7. Pack Sizes: 100 mg. Product ID: B0084-457654. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Angiotensin A | Angiotensin A is a potent endogenous vasoconstrictor octapeptide. It is a derivative of angiotensin II (Ang II) that differs from Ang II in having alanine instead of aspartic acid as the first amino acid. It shows similar affinity for AT1 and AT2 receptors as angiotensin II with Ki values of 1.6 and 2.3 nM in vitro. It causes pressor and renal vasoconstrictor effects in rodents by the AT1 receptor. It is inhibited by Candesartan but not by AT2 receptor ligands in vivo. It also increases inositol phosphate accumulation with a similar potency to Ang II with EC50 value of 6.7 nM. Group: Pharmaceutical. CAS No. 51833-76-2. Pack Sizes: 10 mg. Product ID: BAT-015367. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Atosiban | Atosiban, a nonapeptide, desamino-oxytocin analogue, is a competitive inhibitor of the hormones oxytocin and vasopressinv. It inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. It antagonises uterine contractions and induces uterine quiescence in human pre-term labour at the recommended dosage. It was developed by Ferring Pharmaceuticals in Sweden. It is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. Uses: Atosiban is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. Group: Pharmaceutical. CAS No. 90779-69-4. Pack Sizes: 10 mg. Product ID: BAT-010038. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| IPI-549 | IPI-549, a dihydroisoquinolin derivative, has been found to be a phosphatidylinositol 3 kinase gamma inhibitor, could exhibit antineoplastic activity in solid tumors. It is still under Phase I trial. IC50: 16 nM (PI3Kγ), 3.2 μM (PI3Kα), 3.5 μM (PI3Kβ), >8.4 μM (PI3Kδ). Group: Pharmaceutical. CAS No. 1693758-51-8. Pack Sizes: 50 mg. Product ID: B0084-475947. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| MKC-3946 | MKC-3946 is a potent inhibitor of inositol-requiring enzyme 1α (IRE1α). It inhibits XBP1 mRNA splicing and exhibits cytotoxicity against AML cells. MKC-3946 leads to modest growth inhibition in MM cells but has no effect on normal mononuclear cells in vitro. Group: Pharmaceutical. CAS No. 1093119-54-0. Pack Sizes: 300 mg. Product ID: B0084-054003. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Netupitant | Netupitant is a selective neurokinin 1 (NK1) receptor antagonist with potential antiemetic activity. Netupitant competitively binds to and blocks the human substance P/NK1 receptors in the central nervous system (CNS), thereby inhibiting NK1-receptor binding of the endogenous tachykinin neuropeptide substance P (SP), which may result in the prevention of chemotherapy-induced nausea and vomiting (CINV). SP is found in neurons of vagal afferent fibers innervating the brain-stem nucleus tractus solitarii and the area postrema, which contains the chemoreceptor trigger zone (CTZ), and may be elevated in response to chemotherapy. The NK-receptor is a G-protein receptor coupled to the inositol phosphate signal-transduction pathway and is found in both the nucleus tractus solitarii and the area postrema. On 10/10 2014 FDA approved netupitant for the treatment of nausea and vomiting in patients undergoing cancer chemotherapy. Group: Pharmaceutical. CAS No. 290297-26-6. Pack Sizes: 50 mg. Product ID: B2693-465324. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| PF-04691502 | PF-04691502 is an agent targeting the phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR) in the PI3K/mTOR signaling pathway, with potential antineoplastic activity. It inhibits both PI3K and mTOR kinases, which may result in apoptosis and growth inhibition of cancer cells overexpressing PI3K/mTOR. Activation of the PI3K/mTOR pathway promotes cell growth, survival, and resistance to chemotherapy and radiotherapy. mTOR, a serine/threonine kinase downstream of PI3K, may also be activated independent of PI3K. Group: Pharmaceutical. CAS No. 1013101-36-4. Pack Sizes: 50 mg. Product ID: B0084-456382. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Seletalisib | Seletalisib is a selective Phosphatidylinositol 3 kinase delta inhibitor originated by UCB. It is an immunomodulator. Phaes I clinical trials for Plaque psoriasis, phaes II clinical trials for Sjogren's syndrome and phaes III clinical trials for Immunodeficiency disorders is on-going. Group: Pharmaceutical. CAS No. 1362850-20-1. Pack Sizes: 100 mg. Product ID: B2693-475366. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Tricirbine | Triciribine is a potent AKT inhibitor and a cell-permeable tricyclic nucleoside molecule with potential antineoplastic activity. Akt-1, -2, and -3 are serine/threonine protein kinases in the phosphatidylinositol (PI3)-kinase signalling pathway that play a critical role in the regulation of cell proliferation and survival. Following recruitment of Akt to the plasma membrane, phosphorylation at threonine 308 and serine 473 (Akt-1 numbering) by phosphoinositide-dependent kinases (PDK) 1 and 2 results in full activation of the enzyme. Triciribine is a cell-permeable tricyclic nucleoside that inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3. It does not inhibit phosphatidylinositol 3 (PI3)-Kinase or PDK1, the direct upstream activators of Akt, nor does it inhibit PKC, PKA, ERK1/2, serum- and glucocorticoid-inducible kinase, p38, STAT3, or JNK signalling pathways. Triciribine effectively inhibits growth of Akt-overexpressing human cancer cell lines in vitro with 50% inhibition at ~5-10 μM. It also inhibit growth of tumor xenografts in mice by greater than 80% at a dose of 1 mg/kg/day. Group: Pharmaceutical. CAS No. 35943-35-2. Pack Sizes: 100 mg. Product ID: B1370-090988. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| XL147 | Pilaralisib is a Class 1 phosphatidylinositol 3 kinase (PI3K) family inhibitor. It is an orally bioavailable small molecule, targeting the class I PI3K family of lipid kinases. It is a pyrimidine derivatives compound discovered by Exelixis Inc. It has potential antineoplastic activity. It binds to class 1 PI3Ks in an ATP-competitive manner by inhibiting the production of the secondary messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3) and inhibiting the activation of the PI3K signaling pathway. Uses: Pilaralisib has potential antineoplastic activity. Group: Pharmaceutical. CAS No. 956958-53-5. Pack Sizes: 300 mg. Product ID: B0084-258924. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
